MedTrace Logo

Role of Oral Lactoferrin in Prevention of Recurnt Bacterial Vaginosis in Pregnancy

NCT05669963 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2023-01-03

No results posted yet for this study

Summary

lactoferrin is believed to modulate immunity and help in prevention of recurrent bacterial vaginosis.In this study, the role of lactoferrin is assessed during third trimester of pregnancy.

Conditions

  • Bacterial Vaginosis | Vaginal | Microbiology

Interventions

DRUG

lactoferrin

study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin). And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Rania Samy Ezzat, MD · Lecturer of obstetrics and Gynecology, Faculty of Medicine, Zagazig University

  • Amal Mohamed Alanwar, MD · Professor of obstetrics and Gynecology, Faculty of Medicine, Zagazig University

  • Safaa Abdelsalam Ibrahim, MD · Professor of obstetrics and Gynecology, Faculty of Medicine, Zagazig University

  • Marian Asaad Gerges, MD · Assistant Professor of Microbiology and Immunology Faculty of Medicine Zagazig University

  • Khoulh Al Mahdi Anbeeh Al Barhami, MBBCH · Master's degree candidate

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-01-31
Completion
2023-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669963 on ClinicalTrials.gov